Table 2.
Therapies Received During Admission
| Variables | Azithromycin (n = 428) | Beta-lactam (n = 167) |
p-value CI |
|---|---|---|---|
| Respiratory medications during admission | |||
| Short acting beta-2 agonist (SABA), n (%) | 427 (99.8) | 166 (99.4) | 0.49 |
| Short acting muscarinic antagonist (SAMA), n (%) | 422 (98.6) | 167 (100) | 0.12 |
| Long acting beta-2 agonist (LABA), n (%) | 98 (22.9) | 22 (13.2) | 0.008 |
| Long acting muscarinic antagonist (LAMA), n (%) | 68 (15.9) | 7 (4.2) | < 0.001 |
| Inhaled corticosteroid (ICS), n (%) | 141 (32.9) | 63 (37.7) | 0.27 |
| Theophylline | 4 (0.9) | 1 (0.6) | 0.69 |
| Roflumilast | 0 (0.0) | 1 (0.6) | 0.11 |
|
Corticosteroids, n (%) IV therapy PO therapy |
422 (98.6) 403 95.5) 322 (76.3) |
164 (98.2) 159 (97) 91 (55.5) |
0.95 0.56 < 0.001 |
| Duration of therapy (days), (mean ± SD) | 4.2 ± 2.9 | 5.2 ± 2.7 | < 0.001 |
| Cumulative equivalent dose of prednisone/day (mg), (mean ± SD) | 127 ± 50.6 | 132 ± 61.3 | 0.33 |
| Escalation of O2 requirement | 252 (58.9) | 52 (31.1) | < 0.001 |
| Respiratory medications upon discharge | |||
| Long-acting beta-agonist, n (%) | 255 (59.6) | 59 (35.3) | < 0.001 |
| Long-acting muscarinic antagonist, n (%) | 176 (41.1) | 32 (19.2) | < 0.001 |
| Bacterial infections during hospital stay, n (%) | 8 (1.9) | 10 (6) | 0.01 |